

<b>Policy Name:</b>	<b>Fabrazyme (agalsidase beta) and Elfabrio (pegunigalsidase alfa)</b>	<b>Policy #:</b>	<b>2474P</b>
---------------------	--	------------------	--------------

## Purpose of the Policy

The purpose of this policy is to establish the criteria for coverage of enzyme replacement therapies used for Fabry disease; Fabrazyme (agalsidase beta) and Elfabrio (pegunigalsidase alfa).

## Statement of the Policy

Health Alliance Medical Plans will approve the use of Fabrazyme (agalsidase beta) or Elfabrio (pegunigalsidase alfa) under the Specialty Medical benefit when the following criteria have been met.

## Criteria

### 1. Coverage Criteria for Fabry disease

- 1.1 Diagnosis of Fabry disease confirmed by one of the following;
  - Gene testing results with significant disease related mutations in the GALA/GLA gene
  - Decreased blood levels of alpha-galactosidase A (< 5% of normal)
- 1.2 Age 2 years or older (Fabrazyme) or 18 years or older (Elfabrio)
- 1.3 Prescribed by a gene doctor or other specialist in the treatment of Fabry disease
- 1.4 Documented presence of clinical manifestations (e.g., kidney related, brain/nerve related, heart related)

### 2. Exclusion Criteria

- 2.1 Marginal alpha- galactosidase A levels AND a lack of clinical manifestation
- 2.2 Concomitant therapy of both Fabrazyme and Elfabrio or either in addition to Galafold

### 3. Approval Period

- 3.1 Initial: 12 months
- 3.2 Reauthorization: 12 months with documentation to support clinical benefit from therapy

## CPT Codes

--	--

## HCPCS Codes

J0180	Injection, agalsidase beta, 1mg (Fabrazyme)
J2508	Injection, pegunigalsidase alfa-iwxj, 1 mg (Elfabrio)

## References

1. Fabrazyme (agalsidase beta) [prescribing information]. Cambridge, MA: Genzyme Corporation; July 2024.
2. Elfabrio (pegunigalsidase alfa) [prescribing information]. Cary, NC: Chiesi USA; May 2024.
3. Ortiz, A et al. Fabry disease revisited: Management and treatment recommendations for adult patients. *Mol Genet Metab.* 2018;123(4):416–427.
4. Hopkin R, Jefferies J, Laney D, et al. The management and treatment of children with Fabry disease: A United States-based perspective. *Molecular Genetics and Metabolism*, 2016; 117, 104–113.
5. Henderson, N et al. Fabry disease practice resource: Focused revision. *J Genet Couns.* 2020;29(5):715–717.

**Created Date:** 04/06/16

**Effective Date:** 04/06/16

**Posted to Website:** 01/01/22

**Revision Date:** 10/02/24

### DISCLAIMER

This Medical Policy has been developed as a guide for determining medical necessity. The process of medical necessity review also entails review of the most recent literature and physician review. Medical Policy is not intended to dictate to providers how to practice medicine. Providers are expected to exercise their medical judgment in providing the most appropriate care. Health Alliance encourages input from providers when developing and implementing medical policies. Benefit determinations are based on applicable contract language in the member's Policy/ Subscription Certificate/ Summary Plan Description. This Medical Policy does not guarantee coverage. There may be a delay between the revision of this policy and the posting on the web. Please contact the Health Alliance Customer Service Department at 1-800-851- 3379 for verification of coverage.